HiberCell
hibercell.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$60M
1 round on record
Latest round
$60M
Venture round · Feb 2019 · 7 yr ago
Team
51-200
employees, estimated range
Backers
1
ARCH Venture Partners
The money's age
Long since its last round
92 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 16, 2021
Acquisition HiberCell buys Genuity Science for $100 million · bizjournals.com
Jul 7, 2020
Acquisition HiberCell Announces Acquisition of Biothera Pharmaceuticals · PRNewswire
Feb 7, 2019
Raised a round Venture round $60M · MedCity News
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2019 | $60M | — | MedCity News |
Backed byfrom the funds' portfolios and accelerator catalogs
ARCH Venture Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable…
SirnaMed is committed to developing innovative therapies that directly target the cause of cancer development, progression and treatment…
SOLA Biosciences develops JUMP70 platform therapies targeting protein misfolding in ALS, Parkinson’s, and other conformational diseases.
By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a…
Discover AbelZeta Pharma's global leadership in pioneering T cell-based therapies targeting cancer, inflammation, & immunological issues…
Orca empowers fraud fighters with effective tools to combat fraud.
Overview
Developing therapies targeting adaptive-stress driven vulnerabilities to combat treatment resistance, cancer relapse, and metastasis.
News
HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC)
ROSEVILLE, Minn., April 14, 2026 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the preclinical poster presentation titled,Combinat
Read more
Report
HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted
Read more
Report
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
Read more
Report
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
HC-5404-FU PERKi Program is Currently in a Phase 1a Clinical Trial for the Treatment of Solid TumorsNEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastas
Read more
Report
HiberCell's Genuity buyout brings $100M, plus alliances with Ionis and AbbVie
Startup HiberCell has acquired Genuity Science, a marriage that brings together two companies that apply AI and machine learning to drug research. HiberCell says Genuity will help the company identify and validate new pathways in how cancer starts and pro
Read more
Report
HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization
NEW YORK& BOULDER, Colo.---- Biodesix, Inc. today announced an agreement with HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, to further the development of an enzyme-linked immunosorbent assay as a compa
Read more
Report
HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization
Read more
Report
HiberCell Announces Acquisition of Biothera Pharmaceuticals
/PRNewswire/ -- HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced the acquisition of Biothera...
Read more
Report
Startup HiberCell gets more than $60M to focus on mechanism behind cancer metastasis, recurrence
The New York-based company has two programs in preclinical discovery, based on research conducted at Mount Sinai's Tisch Cancer Institute.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Roseville
United States
HQ
Contact Us
50-200 est. staff
2825 Fairview Ave. N., Roseville, MN 55113 USA
Financials
Total raised
$60M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2019 | $60M | Details |